Atrial fibrillation and stroke prevention

Research output: Contribution to journalReview article

Standard

Atrial fibrillation and stroke prevention. / Lip, Gregory; Lim, Hoong.

In: The Lancet Neurology, Vol. 6, No. 11, 01.11.2007, p. 981-93.

Research output: Contribution to journalReview article

Harvard

APA

Vancouver

Author

Bibtex

@article{16442f8eea264e6fba25ac323debe377,
title = "Atrial fibrillation and stroke prevention",
abstract = "Atrial fibrillation (AF) is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Anticoagulant therapy reduces the risk of stroke, and the greatest benefit is seen in patients at highest absolute risk. Aspirin is a less effective alternative, and any benefit of aspirin might be due to its favourable effects on arterial thrombosis caused by vascular disease. However, anticoagulant therapy remains underused, particularly in the elderly, who probably have the most to gain from stroke prevention owing to their high absolute risk. The underuse of anticoagulation might also be related to uncertain risk of thromboembolism in individual patients and a perceived overestimation of the benefit and underestimation of risk of bleeding with warfarin in clinical trials. In this Review, we summarise the data for and against warfarin and aspirin therapies and discuss the clinical assessments and risk stratifications that guide the use of antithrombotic therapy for stroke prevention in patients with AF. Possible barriers to the uptake of anticoagulation therapy are also discussed.",
author = "Gregory Lip and Hoong Lim",
year = "2007",
month = nov,
day = "1",
doi = "10.1016/S1474-4422(07)70264-8",
language = "English",
volume = "6",
pages = "981--93",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Elsevier",
number = "11",

}

RIS

TY - JOUR

T1 - Atrial fibrillation and stroke prevention

AU - Lip, Gregory

AU - Lim, Hoong

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Atrial fibrillation (AF) is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Anticoagulant therapy reduces the risk of stroke, and the greatest benefit is seen in patients at highest absolute risk. Aspirin is a less effective alternative, and any benefit of aspirin might be due to its favourable effects on arterial thrombosis caused by vascular disease. However, anticoagulant therapy remains underused, particularly in the elderly, who probably have the most to gain from stroke prevention owing to their high absolute risk. The underuse of anticoagulation might also be related to uncertain risk of thromboembolism in individual patients and a perceived overestimation of the benefit and underestimation of risk of bleeding with warfarin in clinical trials. In this Review, we summarise the data for and against warfarin and aspirin therapies and discuss the clinical assessments and risk stratifications that guide the use of antithrombotic therapy for stroke prevention in patients with AF. Possible barriers to the uptake of anticoagulation therapy are also discussed.

AB - Atrial fibrillation (AF) is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Anticoagulant therapy reduces the risk of stroke, and the greatest benefit is seen in patients at highest absolute risk. Aspirin is a less effective alternative, and any benefit of aspirin might be due to its favourable effects on arterial thrombosis caused by vascular disease. However, anticoagulant therapy remains underused, particularly in the elderly, who probably have the most to gain from stroke prevention owing to their high absolute risk. The underuse of anticoagulation might also be related to uncertain risk of thromboembolism in individual patients and a perceived overestimation of the benefit and underestimation of risk of bleeding with warfarin in clinical trials. In this Review, we summarise the data for and against warfarin and aspirin therapies and discuss the clinical assessments and risk stratifications that guide the use of antithrombotic therapy for stroke prevention in patients with AF. Possible barriers to the uptake of anticoagulation therapy are also discussed.

U2 - 10.1016/S1474-4422(07)70264-8

DO - 10.1016/S1474-4422(07)70264-8

M3 - Review article

C2 - 17945152

VL - 6

SP - 981

EP - 993

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 11

ER -